Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 107

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 107
---
 learning,
a form of artificial intelligence (“AI”). Our diagnostic tests analyze cell populations, including cancer and cancer-related
cells, that are indicative of a specific diseased state.

We were formed as a Delaware corporation on March
26, 2014. On June 15, 2016, we formed OncoSelect Therapeutics, LLC (“OncoSelect”),a
Delaware limited liability company and our wholly owned subsidiary which is a preclinical-stage biopharmaceutical discovery company that
has advanced our discoveries of novel potential cancer therapies that specifically and selectively target a broad spectrum of cancer cells
that have been grown in petri dishes without harm to healthy cells. We expect to present our findings at conferences and publish the results
of our research this year and seek strategic partners that have the resources to advance our therapeutic discoveries.

On August 14, 2023, we formed Precision Pathology
Laboratory Services, LLC (“PPLS”), a Texas limited liability company and our wholly owned subsidiary, which performs our clinical
laboratory services, including CyPath Lung operations. Research and optimization of our platform technologies for in vitro
diagnostics and therapeutic technologies are conducted in laboratories at The University of Texas at San Antonio and PPLS in San Antonio,
Texas.

In September 2023, through our wholly owned subsidiary
PPLS, we acquired the assets of Village Oaks Pathology Services, P.A. (“Village Oaks”), a Texas professional association d/b/a
Precision Pathology Services, including a clinical anatomic and clinical pathology laboratory and related services business in San Antonio,
Texas. The laboratory is accredited by the College of American Pathologists (“CAP”) and certified under the Clinical Laboratory
Improvement Amendments of 1988 (“CLIA”).

Our first diagnostic test, CyPath
Lung, addresses the need for noninvasive detection of early-stage lung cancer. Lung cancer is the leading cause of cancer-related deaths
worldwide. Physicians order CyPath Lung to assist in their assessment and care of patients who are at high risk for lung
cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely
intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.
CyPath Lung has the potential to increase overall diagnostic accuracy of lung cancer, which could lead to increased survival,
fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

CyPathLung uses flow cytometry technology
to detect and